Serotonin syndrome: how to recognize it and what to do

What serotonin syndrome is

Serotonin syndrome is a hyperserotonergic state caused by too much serotonin at CNS receptors. It sits on a spectrum from mild (jitters and mild autonomic activation, often seen with a single SSRI dose increase) to severe (hyperthermia, muscle rigidity, seizures, death). Most cases in real practice are mild and resolve quickly. Severe cases are uncommon but require ICU-level management.

The classic clinical triad:

• Mental status changes: agitation, restlessness, confusion, anxiety, delirium.
• Autonomic instability: tachycardia, hypertension, hyperthermia, diaphoresis, mydriasis, GI hyperactivity (diarrhea).
• Neuromuscular hyperactivity: clonus (spontaneous, inducible, or ocular), hyperreflexia, tremor, muscle rigidity, ataxia.

The neuromuscular findings are more prominent in the lower extremities than the upper extremities, which is a distinguishing feature from neuroleptic malignant syndrome.

Hunter serotonin toxicity criteria

The Hunter criteria (Dunkley et al., QJM 2003) are the modern diagnostic gold standard, more sensitive and specific than the older Sternbach criteria. A patient meets Hunter criteria for serotonin toxicity if they have received a serotonergic agent AND one of:

• Spontaneous clonus
• Inducible clonus plus agitation or diaphoresis
• Ocular clonus plus agitation or diaphoresis
• Tremor plus hyperreflexia
• Hypertonia plus temperature above 38 °C plus ocular clonus or inducible clonus

Any one of these bullet points meets criteria. Clonus is the most useful physical finding.

Which drug combinations cause it

Combinations are the classic trigger. Monotherapy at therapeutic doses rarely causes serotonin syndrome.

High-risk combinations (frequently reported cases):

• SSRI or SNRI plus an MAOI (phenelzine, tranylcypromine, isocarboxazid, selegiline, linezolid, methylene blue). This is the reason for the 14-day washout between an SSRI and an MAOI, and 5 weeks after fluoxetine because of norfluoxetine's long half-life.
• SSRI or SNRI plus tramadol. Very common in real practice. Tramadol is a weak SNRI itself plus a serotonergic agent. See our SSRI plus tramadol interaction page.
• SSRI or SNRI plus linezolid (antibiotic). Linezolid has MAOI activity. FDA has published safety communications about this combination.
• MDMA (Ecstasy) plus SSRIs or MAOIs.
• Meperidine plus MAOIs. Historical high-mortality combination.
• Multiple serotonergic drugs stacked: SSRI plus SNRI plus triptan plus dextromethorphan plus tramadol becomes progressively higher risk.

Moderate-risk situations:

• Adding an SSRI or SNRI at any dose to a patient on tramadol, methadone, fentanyl (fentanyl is weakly serotonergic).
• Rapid dose escalation of an SSRI or SNRI.
• Overdose of a single serotonergic drug.
• Adding trazodone, nefazodone, mirtazapine, or a triptan to an existing SSRI or SNRI. The theoretical risk is real but rare cases in practice.

Common combinations that are usually fine but can occasionally trigger it:

• SSRI plus a triptan (sumatriptan, rizatriptan). FDA published a safety communication in 2006; subsequent analysis found the risk is very low but not zero.
• SSRI plus ondansetron.
• SSRI plus dextromethorphan (cough syrup).

Serotonergic supplements and drugs of abuse:

• St. John's wort has SSRI-like activity and can cause serotonin syndrome when combined with other serotonergic drugs.
• L-tryptophan supplements.
• 5-HTP supplements.
• MDMA, DMT, ayahuasca.

Distinguishing from NMS and anticholinergic toxicity

Serotonin syndrome is often confused with neuroleptic malignant syndrome or anticholinergic toxicity. Key distinguishing features:

Serotonin syndrome vs NMS:

• Serotonin syndrome: fast onset (hours), lower-extremity clonus, hyperreflexia, GI hyperactivity, drugs are serotonergic
• NMS: slow onset (days to weeks), lead-pipe rigidity, hyporeflexia, altered mental status, drugs are dopamine antagonists

Serotonin syndrome vs anticholinergic toxicity:

• Serotonin syndrome: sweaty, hyperreflexia, GI hyperactivity (diarrhea)
• Anticholinergic: dry skin, absent bowel sounds, urinary retention, hyporeflexia

The mnemonic for anticholinergic toxicity (dry as a bone, red as a beet, hot as a hare, blind as a bat, mad as a hatter) contrasts with serotonin syndrome, which is characteristically wet (sweaty), with active bowel sounds, and shows brisk reflexes.

Management

Stop all serotonergic drugs immediately.

Mild cases (mostly restless and jittery, no rigidity, temp below 38.5 °C):

• Supportive care
• Benzodiazepines for agitation (lorazepam 1 to 2 mg IV or IM)
• Monitor for 24 to 72 hours; most resolve

Moderate cases (autonomic instability, moderate rigidity, temp 38.5 to 40 °C):

• Above measures
• IV fluids
• Cyproheptadine 12 mg oral load, then 2 mg every 2 hours until symptoms resolve (max 32 mg/day). Cyproheptadine is a 5-HT2A antagonist and is the specific antidote when practical.
• Continuous cardiac monitoring

Severe cases (rigidity with temp above 41 °C, seizures, hemodynamic instability):

• ICU admission
• Aggressive cooling
• Neuromuscular blockade (non-depolarizing, since succinylcholine can worsen hyperthermia)
• Intubation and sedation
• Correction of rhabdomyolysis, DIC, renal failure as they develop

Avoid:

• Bromocriptine and other dopamine agonists (may worsen)
• Antipyretics (do not work because hyperthermia is muscle-driven, not hypothalamic)
• Physical restraints (can worsen rhabdomyolysis)

Prevention

• Recognize the drug combinations and avoid them or accept the risk with informed monitoring.
• Standard 14-day MAOI washout for switching SSRIs to MAOIs, 5 weeks after fluoxetine.
• Tramadol substitution when possible for patients on SSRIs or SNRIs. Suzetrigine, acetaminophen, NSAIDs (if safe), or opioids that are not serotonergic (morphine, oxycodone at appropriate doses) are alternatives. See our Journavx state of practice.
• Documenting risk in the chart for patients on multi-serotonergic regimens.
• Cross-taper caution: during antidepressant cross-tapers, use lowest effective overlap doses and monitor closely. See the antidepressant switching planner.

Common questions

How common is serotonin syndrome? Mild cases are common; severe cases are uncommon. Exact incidence is unknown because mild cases go unrecognized. Estimated 15 percent of patients on serotonergic drugs have at least mild symptoms at some point, though most do not meet formal Hunter criteria. Severe cases requiring ICU care are rare.

Can I take an SSRI and a triptan for migraine? Yes, in most cases. The FDA 2006 safety communication about SSRI plus triptan combinations generated concern, but subsequent large database studies found the actual risk of serotonin syndrome is very low. Most headache and psychiatry organizations no longer recommend against the combination. Discuss with the prescriber if there are specific concerns.

What about SSRI plus dextromethorphan (cough medicine)? Theoretical risk, real cases are rare at cough-syrup doses. At higher doses of dextromethorphan (Auvelity's therapeutic dose in depression), the pharmacology is different and the combination is dosed intentionally. See our Auvelity state of practice.

Is MDMA use with SSRIs dangerous? Yes, potentially life-threatening. SSRIs blunt the euphoric effect of MDMA (which pushes people to redose, worsening the situation) and both drugs raise serotonin. Fatal cases have been reported.

Can serotonin syndrome happen from a single drug? Rarely, at very high doses (SSRI overdose, for example). Most cases involve combinations.

How fast does it come on? Fast. Symptoms usually develop within hours of starting the offending combination or dose escalation. This is one of the features distinguishing it from NMS, which develops over days to weeks.

How is it different from anxiety or panic? Anxiety and panic do not produce clonus, hyperreflexia, or hyperthermia. If a patient on a serotonergic drug has restlessness plus muscle jerks (clonus), fever, or elevated BP and pulse, serotonin syndrome should be on the differential.

Should I stop my SSRI if I need surgery? Not usually. Standard practice is to continue SSRIs through surgery. The exception: if the surgical team plans to use tramadol, meperidine, methylene blue, linezolid, or MAOIs (rare), coordinate with the surgery team and prescriber in advance. Fentanyl is weakly serotonergic but almost universally used and rarely causes clinically significant syndrome.

Sources

• Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120.
• Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642.
• FDA. Public Health Advisory. Combined use of 5-hydroxytryptamine receptor agonists (triptans), SSRIs, and SNRIs may result in life-threatening serotonin syndrome. July 19, 2006.
• FDA Drug Safety Communication: Serious CNS reactions possible when linezolid or intravenous methylene blue given to patients taking certain psychiatric medications. Updated 2011.
• Ables AZ, Nagubilli R. Prevention, diagnosis, and management of serotonin syndrome. Am Fam Physician. 2010;81(9):1139-1142.